Cost-Effectiveness of New Quadruple Therapy Compared With Standard Treatment for Patients With Heart Failure in China

被引:2
|
作者
Huang, Yun [1 ]
Zhou, Hua [1 ]
Fang, Chongbo [1 ]
Ma, Lili [1 ]
Zhang, Yuyu [1 ]
Rong, Weibo [1 ]
Liu, Xiaoli [2 ,5 ]
Ye, Honghua [3 ,4 ]
机构
[1] Ningbo Univ, Li Huili Hosp, Ningbo Med Ctr, Dept Pharm, Ningbo, Zhijiang, Peoples R China
[2] Hunan Univ Tradit Chinese Med, Affiliated Hosp 2, Caie North Rd 233, Changsha, Hunan, Peoples R China
[3] Ningbo Univ, Li Huili Hosp, Ningbo Med Ctr, Dept Cardiol, Xingning Rd 57, Ningbo 315040, Zhijiang, Peoples R China
[4] Ningbo Univ, Li Huili Hosp, Ningbo Med Ctr, Dept Cardiol, Xingning Rd 57, Ningbo 315040, Zhijiang, Peoples R China
[5] Hunan Univ Tradit Chinese Med, Affiliated Hosp 2, Caie North Rd 233, Changsha 410119, Hunan, Peoples R China
关键词
SGLT2; inhibitors; heart failure; cost-effectiveness; China; ECONOMIC BURDEN; DAPAGLIFLOZIN; PREVALENCE; MANAGEMENT; DISEASES;
D O I
10.1097/FJC.0000000000001476
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Supplemental Digital Content is Available in the Text. This study aimed to compare the cost-effectiveness of the new quadruple therapy regimen of adding sodium-glucose-linked transporter 2 (SGLT2) inhibitors, with standard treatment for patients with heart failure (HF) in China. From the payer's perspective, the dates of cardiovascular event recurrences were extracted from a meta-analysis including 6 trials, combined with the treatment cost for patients with HF in China to construct a Markov model. The outcomes included per capita medical costs and incremental cost-effectiveness ratio, using quality-adjusted life years (QALYs) data. Single-factor, probability sensitivity analysis, and scenario analysis were used to explore the potential uncertainties of the model. The per capita costs of the new quadruple therapy regimen and standard treatment were $87441.26 and $87087.54, respectively. The new regimen was associated with a mean of 21.44 QALYs gained, compared with 18.60 QALYs gained with the standard treatment. The incremental cost-effectiveness ratio was $124.03 per QALY gained. The sensitivity analysis revealed that changes in the parameters within the set range did not affect the model results. In China, compared with standard treatment, the new quadruple therapy regimen with SGLT2 inhibitors reduce the frequency of cardiovascular events among patients with HF, and it has economic advantages.
引用
收藏
页码:86 / 92
页数:7
相关论文
empty
未找到相关数据